News FDA clears first treatment for Prader-Willi syndrome Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for excessive eating in rare disorder Prader-Willi syndrome.
Views & Analysis Bringing social media listening into R&D After her daughter was diagnosed with Prader-Willi syndrome, Maria Picone used social media listening and AI analytics to find out the best ways to manage the rare disease.
Views & Analysis Millendo’s Julia Owens on leadership in rare diseases Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome.
News Zafgen ends development of Prader-Willi drug Share price plummets after biotech said drug is unsafe.
News Digital support reduces GLP-1 dose needed for weight loss Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
